Several arenaviruses endemic to South America (Junin, Machupo, and Guanarito) and Africa (Lassa) are known to cause frequently fatal haemorrhagic fever. With the exception of ribavirin, which has demonstrated efficacy in cases of Lassa fever, there is no other effective therapeutic for the treatment of arenaviral haemorrhagic fever. We have recently reported that consensus interferon-α α (IFN alfacon-1) can protect hamsters from lethal Pichinde virus (PCV) infection, which serves as a model for acute arenaviral disease in humans. Here we demonstrate highly effective therapy through the combined use of ribavirin with IFN alfacon-1 for the treatment of PCV infection in hamsters. Ribavirin was given orally, twice per day for 7 days, and IFN alfacon-1 was administered intraperitoneally once per day for 10 days. Treatments were initiated 1-5 days post-virus challenge using various dose combinations, many of which were less than optimal when the drugs were given independently. Combining suboptimal doses of ribavirin (5-10 mg/kg/day) with IFN alfacon-1 (5-10 µ g/kg/day), we were able to demonstrate increased protection from mortality, reduced viral burden and liver disease, and greatly extended survival times as compared to treatments where drugs were administered alone. Our data indicate that combination therapy results in synergistic activity that may slow down the progression of the disease and decrease fatality rates associated with severe arenaviral infections in humans. Further, combination therapy reduces the effective dosage of ribavirin, which would serve to limit its toxicity.
Introduction
In West Africa, infection with the Old World arenavirus, Lassa, by far has had the greatest impact on public health by haemorrhagic fever of arenaviral origin killing an estimated 5,000 people per year (Fisher-Hoch et al., 2000) . A growing number of New World arenaviruses ( Junin, Machupo, Guanarito and Sabia) can also cause severe and often fatal haemorrhagic disease in humans (Charrel & de Lamballerie, 2003) . With the continued encroachment into rural areas of South America where the rodent reservoirs harbouring many of these viruses exist, it is likely that more of these deadly agents will be uncovered in the near future. Importantly, these deadly arenaviruses are considered potential bioterrorism agents underscoring the need for effective therapeutics and prophylaxis in the event of malicious release. Pichinde virus (PCV) is a related New World arenavirus that is highly pathogenic for hamsters, but is non-pathogenic for humans (Buchmeier et al., 1974; , which makes it an attractive surrogate for pre-clinical evaluations of promising drugs targeted at the treatment of severe arenaviral diseases. PCV infection in the hamster produces a fulminating disease that ends in terminal shock in the face of high levels of systemic virus (Murphy et al., 1977; Smee et al., 1993) . The observed tissue pantropism and disease manifestations are similar to what has been described in cases of human Lassa fever (Walker et al., 1982) . The PCV hamster infection model can be worked with safely under biosafety level-2 conditions greatly facilitating comprehensive antiviral evaluations likely to be predictive of efficacy against highly-pathogenic arenaviruses in humans.
With the exception of ribavirin, which has been shown to be efficacious in cases of Lassa, Junin and Machupo virus disease in humans (Enria & Maiztegui, 1994; Kilgore et al., 1997; McCormick et al., 1986) , there are no proven effective antiviral compounds for the treatment of arenaviral haemorrhagic fever. A key study reported remarkable efficacy with high-risk Lassa virus-infected individuals when ribavirin therapy was initiated by day 6 following the onset of fever, with more limited effectiveness seen when treatment began 7 days after signs of illness (McCormick et al., 1986) . This study, as well as the treatment of experimental Lassa virus infections in non-human primates ( Jahrling et al., 1980) , underscores the importance of timely therapeutic intervention. In practice, however, by the time clinicians can diagnose arenaviral haemorrhagic disease, effective therapy is often lacking. Further, insofar as the effectiveness of ribavirin, the doses required for successful treatment can be associated with varying degrees of toxicity that primarily consists of widely recognized reversible haemolytic anaemia.
Consensus interferon (IFN alfacon-1) is a FDAapproved drug for the treatment of chronic hepatitis C virus (HCV) infection worldwide. It is a bioengineered, broad-spectrum cytokine containing the most frequently occurring amino acids among human α-IFN subtypes. We recently reported that IFN alfacon-1 is therapeutically effective in combating PCV acute arenaviral disease in hamsters (Gowen et al., 2005) . In this and other evaluations, we routinely use ribavirin, administered via the intraperitoneal (i.p.) route, as the positive control drug since it has been demonstrated to be effective against PCV infection in hamsters (Smee et al., 1993) . We hypothesized that the combination of ribavirin therapy with that of IFN alfacon-1 would result in synergistic activity that may effectively extend the window of treatment and reduce the required amount of ribavirin, which minimizes the toxicity associated with higher monotherapeutic doses. The ability to treat more advanced stages of infection would be of great value for arenaviral diseases that initially do not present distinguishing symptoms that would facilitate rapid clinical recognition. Here we report the evaluation of ribavirin and IFN alfacon-1 combination therapy in the PCV hamster model of acute arenaviral disease.
Materials and methods

Animals and virus
Female 91-100 g LVG/Lak golden Syrian hamsters were obtained from Charles River Laboratories (Wilmington, MA, USA) and acclimatized for 6 days prior to experimentation. All animal procedures complied with guidelines set by the USDA and Utah State University Animal Care and Use Committee. PCV, strain An 4763, was kindly provided by Dr David Gangemi (Clemson University, Clemson, SC, USA) . The virus was passaged once through hamsters. Virus stocks were prepared from pooled livers harvested from infected hamsters. Virus dilutions were made in minimal essential medium (Hyclone, Logan, UT, USA) and infectious inoculum was given bilaterally in two i.p. injections of 0.1 ml.
Test materials
Ribavirin was supplied by ICN Pharmaceuticals Inc. (Costa Mesa, CA, USA) and was prepared in sterile saline. IFN alfacon-1 was provided by InterMune Inc. (Brisbane, CA, USA) at a concentration of 30 µg/ml with a reported activity of 1×10 9 units/mg. IFN alfacon-1 was diluted in sterile saline as needed.
In vivo antiviral evaluations
Groups of 15 hamsters (25 for the placebo group) were challenged with approximately 50 plaque-forming units of PCV and treated as indicated with various doses of ribavirin and/or IFN alfacon-1 at 1-5 days post-virus inoculation. Ribavirin was administered orally (p.o) twice per day for 7 days and IFN alfacon-1 was given i.p. once per day for 10 days. Five animals from each group were sacrificed on day 7, and liver and serum was collected from each animal for the evaluation of infectious virus titre, hepatic icterus, and serum liver enzyme release; the latter served as an indicator of liver dysfunction. The remaining 10 animals (20 for the placebo group) were observed for 21-28 days for death. Three sham-infected controls were included for comparison to establish baselines for all parameters tested.
Liver and serum virus titres
Virus titres were assayed using an infectious cell culture assay as previously described (Smee et al., 1993) . Briefly, a specific volume of liver homogenate or serum was serially diluted and added to triplicate wells of African green monkey kidney (BS-C-1) cell monolayers in 96-well microplates. The viral cytopathic effect (CPE) was determined 6 days post-virus inoculation and the 50% endpoints were calculated as described (Reed & Muench, 1938) .The assay detection range was 1.8-8.5 log 10 cell culture 50% infectious dose (CCID 50 )/0.1 g of liver or ml of serum. In samples presenting with no detectable virus, a value of <1.8 log 10 was assigned. Thus, a mean virus titre value preceded by '<' indicates that at least one of the samples had undetectable levels of virus and, therefore, is likely to be an overestimate of the actual mean viral load. Conversely, in cases where virus exceeded the detection range, a value of >8.5 log 10 was assigned. Thus, samples with a value preceded by '>' are likely to be an underestimate of the actual viral load. For statistical analysis, values of 1.8 or 8.5 log 10 were used for samples with undetectable or saturated virus levels, respectively.
Serum alanine aminotransferase (ALT) determinations
Detection of ALT in serum is an indirect method for evaluating liver damage. Serum ALT levels were measured using the ALT (SGPT) Reagent Set purchased from Pointe Scientific, Inc. (Lincoln Park, MI, USA) following the manufacturer's recommendations. The reagent volumes were adjusted for analysis on 96-well microplates.
Statistical analysis
Fisher's exact test (two-tailed) was used for evaluating increases in total survivors. Log-rank test for survival analysis was performed using JMP statistical software (SAS, Cary, NC, USA) . The Mann-Whitney test (twotailed) was performed to analyse the differences in mean day to death (MDD), virus titres, and serum ALT levels. Wilcoxon ranked sum analysis was used for mean liver score comparisons.
Evaluation of drug combinations
The method employed to determine effects of drug-drug interactions has been previously described by Schinazi and colleagues (Schinazi et al., 1982) and is based on definitions from the work of Valeriote and Lin (1975) .
Results
Determination of suboptimal doses of p.o. ribavirin
Ribavirin has been shown to be effective in humans when given by the p.o. route (Snell, 2001) . Thus, we first investigated the activity of ribavirin by this route of administration in the PCV hamster model, in order to select suboptimal doses for combinatorial studies with IFN alfacon-1. Several of us have previously reported on i.p. delivery of ribavirin for the treatment of PCV infection in hamsters (Smee et al., 1993) . Based on that study, we decided to test daily p.o. doses of 40, 20, 10, and 5 mg/kg/day, for a duration of 7 days, starting 24 h postvirus challenge. As demonstrated in Table 1 , the 20 mg/kg/day dose was the most effective in the context of survival as no animals were lost to the 95% lethal dose (LD 95 ) inoculum of PCV. The 10 and 40 mg/kg/day doses were also effective, as they protected 80% of the hamsters, which was equivalent to the i.p. treatment group of 40 mg/kg/day. At the lower dose of 5 mg/kg/day, only three animals survived. However, by log rank analysis, the difference in survival outcome for this group compared with the placebo was highly significant (P=0.0004), as the animals that died survived appreciably longer (Table 1 ). In addition, hamsters in the other ribavirin groups that failed to survive infectious challenge also had significantly increased mean survival times.
The activity of ribavirin was also evaluated by measuring several virological disease parameters that are commonly increased by day 7 of PCV infection. Consistent with the survival data, we observed marked reductions in liver and systemic virus loads in all groups of ribavirin-treated animals with the high dose i.p. treatment producing the greatest reductions (Table 1) . Increased serum ALT levels, indicative of liver damage characteristic of hepatotropic PCV infection, were also significantly reduced in ribavirintreated hamsters compared with the placebo group. Even the lowest dose of p.o. ribavirin reduced ALT levels by more than 80%, whereas hamsters in the higher dose groups had readings below baseline levels present in the sham-infected normal controls (Table 1 ). In agreement with the ALT and liver virus titre data, only slight liver 
Evaluation of combinatorial ribavirin and IFN alfacon-1 therapy initiated 24 h post-infection
Having observed less than desired protection with 5 mg/kg/day p.o. ribavirin therapy, we chose to focus our efforts on this and the 10 mg/kg/day dose, which was found to be only slightly less effective than the optimal 20 mg/kg/day dose in the initial study (Table 1) . As demonstrated in (Table 2) . We have previously reported that treatment of PCV infection with a 7 day, 20 µg/kg/day IFN alfacon-1 regimen resulted in 70% protection from lethal infection (Gowen et al., 2005) . We hypothesized that by extending treatment by an additional 3 days 100% survival could be achieved. As seen in Table 2 , a 10-day treatment course only slightly increased the rate of survival in the highdose IFN alfacon-1 group; however, when it was combined with sub-optimal ribavirin doses, it resulted in complete protection of PCV-challenged hamsters. As a positive control, a 20 mg/kg/day group of ribavirin was included (Table 2) and it only offered 80% protection as compared to 100% seen in the initial trial (Table 1) . Many of the independent treatments and combinations dramatically extended the mean survival times of animals that perished during the course of study (Table 2) . Notably, the only animal that died in the lowest dose combination of ribavirin and IFN alfacon-1 survived 18 days, almost 10 days longer than the MDD of the placebo-treated animals. No remarkable disruption in weight gain or visible toxic effects could be seen with the highest dose combination of ribavirin and IFN alfacon-1 tested (data not shown).
In concordance with the survival data, good doseresponses to independent treatments with both ribavirin and IFN alfacon-1 were evident when analysing mean virus titres on day 7 of infection ( (Table 2) . At the lower doses, monotherapy with ribavirin and IFN alfacon-1 only partially reduced infectious virus titres. As before, increase in serum ALT activity as a means to quantitatively determine liver damage associated with PCV disease was also analysed. Only the lowest doses of each drug given independently failed to significantly reduce mean ALT values; however, when combined, a striking reduction was observed ( Table 2 ). As seen with the virus titre data, a clear dosedependent decrease in ALT levels was observed. Consistent with the survival and disease parameter profiles, mean liver scores were also significantly reduced by combined lowdose therapy (Table 2) . Synergistic drug-drug interactions were observed for all combinations in the context of survival, with the 5 mg/kg/day ribavirin and 5 µg/kg/day IFN alfacon-1 combination demonstrating the greatest overall synergy.
Delayed treatment of PCV infection with ribavirin and IFN alfacon-1 combination therapy
Based on our previous findings, two combinations of p.o. ribavirin and i.p. IFN alfacon-1 were evaluated for efficacy against more advanced PCV infection. Both combinations were tested in regimens where the start of treatment was delayed from 1-5 days following infectious challenge. The 5 mg/kg/day ribavirin and 10 µg/kg/day IFN alfacon-1 combination administered 24 h post-challenge, served as one of the positive controls for the experiment. As expected, it was highly effective as there was no mortality, systemic and liver virus levels were below the limit of detection, ALT levels were at baseline, and hepatic icterus was minimal for this experimental group (Table 3) . When the initiation of therapy was delayed until day 2, survival decreased to 50% with a MDD 3 days greater than the placebo comparison group where saline was administered in place of drugs. Consistent with the survival data, increased levels of virus and ALT levels were seen with this group of animals; however, liver discolouration was comparable to that seen with the day 1 treatment group ( Treatment initiated 96 h or more after infectious challenge failed to protect hamsters from death; however, survival was significantly extended in the 96 h group (Table 3) . There also appeared to be a slight hint of disease reduction and viral burden with the 96 and 120 h delays in treatment.
The second combination evaluated consisted of 10 mg/kg/day ribavirin with 5 µg/kg/day IFN alfacon-1. As expected, treatment initiated by 24 h produced 100% survival, restricted viral replication to below limits of detection, and dramatically abrogated liver disease manifestations (Table 3) . When therapy began on day 2, 90% of challenged animals survived, and greatly reduced virus titres, ALT levels and liver scores were observed. Treatment initiated 3 days post-virus challenge resulted in 60% protection with animals surviving, on average, more than 10 days longer than those in the placebo group (Table 3) . Moreover, liver virus was reduced by almost 2 log 10 and levels of systemic virus dropped by 1.3 log 10 . As seen with the day 2 initiation group, limited liver damage was noted for the day 3 group (Table 3) . The most impressive finding was the protection seen when treatment was delayed out to 96 h post-infection. In contrast to the 5 mg/kg/day ribavirin and 10 µg/kg/day IFN alfacon-1 combination that had no survivors with the same timing of therapy, 10 mg/kg/day ribavirin and 5 µg/kg/day IFN alfacon-1 treatment protected a highly significant number of animals (70%; log-rank survival analysis, Prob>χ 2 <0.0001) from mortality (Table 3) . Significant viral burden reduction, as well as limitation of hepatic disease was comparable to that seen when treatment was started on day 3. Finally, despite an unimpressive increase in total survivors, highly significant differences by log-rank survival analysis and MDD demonstrate beneficial effects for hamsters where treatment was provided beginning as late as 5 days after infectious challenge with PCV (Table 3) . Further, with the exception of serum viral load, the other disease parameters were all significantly less as compared with the placebo-treated animals. These were encouraging data considering that PCV-infected hamsters can begin to die as early as day 7.
Comparison of independent and combined ribavirin and IFN alfacon-1 therapy starting on days 3 or 4 of PCV infection
The 10 mg/kg/day ribavirin with 5 µg/kg/day IFN alfacon-1 combination was selected for further investigation since it was found to be considerably more effective than the 5 mg/kg/day ribavirin and 10 µg/kg/day IFN alfacon-1 combination when treatment was initiated during later stages of infection (Table 3) after virus challenge. As shown in Table 4 , when combination therapy was initiated by day 3, we again observed similar protection, and reduced viral burden and liver disease. Delaying the start of therapy to day 4 protected 40% of animals from death, decreased viral loads by 2 log 10 and greatly limited ALT levels. Unexplainably however, in contrast to the previous experiment, the day 4 treatment failed to have any statistically significant effect on liver discolouration (Table 4) . Moreover, albeit significant when compared to the placebo group, 40% protection was less than the 70% seen in the first trial ( (Table 4 ). It is important to note that calculations employed to define synergy between ribavirin-IFN alfacon-1 interactions for the various parameters do not take into account SD, thus caution should be used when interpreting the results as a designation of synergistic activity is simply based on mean group values. Collectively, the data suggest that the contribution to overall protection by ribavirin is much greater than that of IFN alfacon-1 when treatment is initiated at later stages of infection.
Discussion
Although considered experimental in the United States for the treatment of severe infections caused by Lassa, Junin and Machupo arenaviruses that cause haemorrhagic disease (Franz et al., 2001) , ribavirin is the only drug that has shown promise and would be indicated in such cases. Administration of ribavirin by the i.p. route has been shown to be effective against PCV infection in hamsters (Smee et al., 1993) The outcome of severe arenaviral infections in humans depends largely upon timely clinical diagnosis with effective management and treatment of disease. In cases of Lassa fever, there is evidence that intervention with ribavirin within 6 days of the onset of fever can have impressive results in patients at highest risk of death from infection (McCormick et al., 1986) . Despite these encouraging data, the need exists for improving current treatment regimens that require doses of ribavirin, which can lead to varying degrees of toxicity. We previously reported on the use of recombinant bio-optimized consensus IFN-α as a potential therapeutic for treating acute arenaviral diseases (Gowen et al., 2005) . Although remarkable efficacy was seen, we were unable to achieve complete protection with the highest tested therapeutic dose of 20 µg/kg/day of IFN alfacon-1, administered for 7 days. Our findings in this study indicate that extending treatment by 3 additional days does not appear to improve the prognosis as only a slight increase (from 70 to 80%) was seen with the aforementioned dose. Interestingly, treatment for 10 days with the sub-optimal dose of 5 µg/kg/day IFN alfacon-1 provided 50% protection (Table 2) , whereas twice as much drug with a 7 day schedule only protected 40% of hamsters from mortality (Gowen et al., 2005) . It should be noted that weaning age hamsters were used in the previously reported work, which may account for some of the observed differences.
The use of ribavirin with IFN alfacon-1 has been reported to be an effective combination for the treatment of HCV infection (da Silva et al., 2002; Fattovich et al., 2003) . Current FDA approval for the treatment of chronic HCV infection makes IFN alfacon-1 an attractive candidate for the potential treatment of other viral diseases since extensive and costly safety profiling in animals and humans has already been conducted, and would facilitate additional indications such as the treatment of arenaviral infections. Combining sub-optimal monotherapeutic treatments of ribavirin and IFN alfacon-1, we were able to achieve remarkable protection indicative of favourable drug-drug interactions when treatment was initiated 24 h postinfection with a highly lethal inoculum of PCV. As a consequence of the upsurge in funding to study agents of
